Oral Stepdown Therapy for Gram‐Negative Bloodstream Infections: A Systematic Review and Meta‐Analysis
Open Access
- 13 August 2026
- journal article
- review article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 56 (8)
Abstract
Background: Early oral step‐down has been proposed as a strategy to optimize antimicrobial use in Gram‐negative bloodstream infections (BSIs). Methods: We performed a systematic review and meta‐analysis of full‐text studies published in English and indexed in MEDLINE and EMBASE up to April 2025. Randomized controlled trials (RCTs) and observational studies including patients with Gram‐negative BSIs managed either with oral step‐down within 5 days of IV therapy or with continued IV therapy were eligible. Risk of bias was assessed using the Cochrane Risk of Bias Tool for RCTs and the Newcastle–Ottawa Scale for observational studies. Results: Of 4120 screened records, 13 studies (3 RCTs and 10 cohort studies) including 10,000 patients met the inclusion criteria; 5016 of enrolled patients (52%) switched to oral therapy, mainly to fluoroquinolones (2992, 59.6%). A lower all‐cause mortality was observed in patients receiving oral step‐down (RR: 0.39, 95% CI: 0.16–0.93; p = 0.034). When stratifying studies according to timing of the switch to oral therapy, no significant difference in mortality was observed in studies with a median switch time ≤ 3 days ( p = 0.29). Conversely, studies with a median switch time > 3 days showed a lower mortality rate in the oral step‐down group, approaching statistical significance ( p = 0.051). No significant differences were found between treatment groups in terms of clinical failure ( p = 0.28). Microbiological failure was significantly less frequent among patients receiving oral step‐down therapy (RR = 0.69, 95% CI: 0.49–0.97; p = 0.032), while adverse event rates were comparable ( p = 0.52). However, sensitivity analyses limited to propensity score–adjusted data demostrated no significant differences in mortality ( p = 0.32) or microbiological failure ( p = 0.076). Conclusions: Oral step‐down therapy for Gram‐negative BSIs appears to be a valuable alternative to prolonged IV treatment, potentially reducing IV exposure, complications and healthcare costs without compromising clinical or microbiological outcomes. Trial Registration: PROSPERO registration number: CRD420251056335Keywords
This publication has 23 references indexed in Scilit:
- Seven vs Fourteen Days of Antibiotics for Gram-Negative Bloodstream InfectionJAMA Network Open, 2025
- Oral switch vs. continued intravenous antibiotic therapy in patients with bacteraemia and sepsis: a systematic review and meta-analysisClinical Microbiology and Infection, 2024
- Early transition to oral therapy in gram-negative bloodstream infections: what is the next step?Clinical Microbiology and Infection, 2024
- Early Switch From Intravenous to Oral Antibiotics for Patients With Uncomplicated Gram-Negative BacteremiaJAMA Network Open, 2024
- Transition to Oral Antibiotic Therapy for Hospitalized Adults With Gram-Negative Bloodstream InfectionsJAMA Network Open, 2024
- Switch to oral antibiotics in Gram-negative bacteraemia: a randomized, open-label, clinical trialClinical Microbiology and Infection, 2023
- Effect of C-Reactive Protein–Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative BacteremiaJAMA, 2020
- Advances in the therapy of bacterial bloodstream infectionsClinical Microbiology and Infection, 2020
- Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae BacteremiaJAMA Internal Medicine, 2019
- Intravenous‐only or Intravenous Transitioned to Oral Antimicrobials for Enterobacteriaceae‐Associated Bacteremic Urinary Tract InfectionPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017